Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

Jesús San-Miguel, Joan Bladé, Ofer Shpilberg, Sebastian Grosicki, Frédéric Maloisel, Chang Ki Min, Marta Polo Zarzuela, Tadeusz Robak, Sripada V.S.S. Prasad, Yeow Tee Goh, Jacob Laubach, Andrew Spencer, María Victoria Mateos, Antonio Palumbo, Tom Puchalski, Manjula Reddy, Clarissa Uhlar, Xiang Qin, Helgi Van De Velde, Hong XieRobert Z. Orlowski

Research output: Contribution to journalArticlepeer-review

123 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology